Triple-Negative Breast Cancer Treatment Market to represent a significant expans
Posted by Bisvjeet on November 27th, 2018
According to the latest market report published by Research Report Insights titled ‘Global Triple-Negative Breast Cancer Treatment Market: Global Industry Analysis, Size, Sales and Forecast By 2026,’ the global triple-negative breast cancer treatment market is projected to reach US$ 727 Mn by the end of 2026and grow at a CAGR of 4.9% during the forecast period.
Global Triple-Negative Breast Cancer TreatmentMarket: Dynamics
Triple-negative breast cancer is a type of cancer that does not have receptors for the hormones oestrogen and progesterone or the protein HER2. Triple-negative breast cancer is arare type of cancer. About 10–20% of breast cancers are found to be triple negative.
Increasing per capita healthcare expenditure and shift towards value-basedcare are the major factorsexpected todrive the growth of themarket fortriple-negative breast cancer treatment over the forecast period.Furthermore, increasing number of research and development activities in therapeutic areas such as cancer and adoption of new treatments for breast cancer are the other factors expected to spur the growth of the market for triple-negative breast cancer over the forecast period.Many new treatments for the triple-negative breast cancer are under study, among which are drug therapies. Introduction of new drugs and treatments will further improve the diagnosis and treatment for triple-negative breast cancer.Likewise, emerging technologies such as nanotechnology for managing triple-negative breast cancer are alsoexpected to drive the growth of the market fortriple-negative breast cancer treatment.The progress in the development of drugs that use novel approaches to kill cancer and inhibit the growth of cancer cells through different therapies in partnership with the other manufactures is also expected to boost the growth of the triple-negative breast cancer market.
However, regulations set up by the FDA and European Union for the approval of cancer drugs are expected to hamperthe growth of the triple-negative breast cancer treatment market.
Global Triple-Negative Breast Cancer TreatmentMarket:Forecast
The global triple-negative breast cancer treatment marketis segmented on the basis of drug type, and distribution channel. On the basis of drug type, the global triple-negative breast cancer treatment market is segmented into doxorubicin, cyclophosphamide, paclitaxel, docetaxel, carboplatin/cisplatin and others.The paclitaxelis expected to be the leading segment in the global triple-negative breast cancer treatment market over the forecast period.The paclitaxel andothers segmentscollectively accounted atotal value share of 73% of the global triple-negative breast cancer treatment marketin 2017. The docetaxelsegment is estimated to have incremental opportunity of US$ 27 Mn between 2016 and 2026.The paclitaxelsegment is expected to hold high share in the globaltriple-negative breast cancer treatment marketastreatment with paclitaxel shows promising results in the overall treatment of triple-negative breast cancer as well asbetter tolerability than the conventional taxanes in metastatic breast cancer.
Geographically, the globaltriple-negative breast cancer treatmentmarket has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. This report assesses the trends driving the growth of each segment and offers analysis and insights into the potential of the triple-negative breast cancer treatment marketin specific regions. North Americaaccounted a large share in the global marketin 2017, and is expected to be the dominant regional market for triple-negative breast cancer treatment over the forecast period, owing to increased prevalence of breast cancer and triple-negative breast cancer.Besides, presence of several key players with a robust distribution network for cancer druganda well-developed healthcare infrastructure are some of the other key factors expected to drive the growth of thetriple-negative breast cancer treatment marketin North America. Asia Pacific is expected to witness rapid growth over the forecast period.
Global Triple-Negative Breast Cancer TreatmentMarket: Competitive Landscape
The report profiles some of the top players operating in the global triple-negative breast cancer treatmentmarket, such as AstraZeneca PLC, Pfizer, Inc., F. Hoffman - La Roche Ltd., Bristol-Myers Squibb Company, Novartis AG, Mylan N.V., Eli Lilly and Company, Celgene Corporation, Sanofi S.A., andJohnson & Johnson Services, Inc.,among others.
Like it? Share it!
About the AuthorBisvjeet
Joined: March 7th, 2018
Articles Posted: 947
More by this author